Clinical trials: Thoracic Neoplasm
Colorectal Cancer, Non-Small Cell Lung Cancer
Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4
Primary Objective: Correlation of the skin and/or eye toxicity grade secondary to Cetuximab or Panitumumab and the SNP profile of the Epidermal Growth Factor Receptor (EGFR) domain III region.
- Trial name
- NCT01726309
- Where
- 10 sites in Ireland
- Volunteers
- 161 people
- Sponsor
- Cancer Trials Ireland
Early Detection of Cancer, Lung Neoplasms
Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening
The purpose of this project is to increase appropriate low-dose computed tomography (LDCT) lung cancer screening through the development and wide dissemination of patient-centered clinical decision support (CDS) tools that (1)…
- Trial name
- NCT04498052
- Testing
- EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening
- Where
- United States
- Volunteers
- 1,855 people
- Sponsor
- University of Utah
Carcinoma, Non-Small-Cell Lung
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
This is a phase II study assessing response rate to PF-06463922 in patients with ROS1 translocation resistant to previous crizotinib therapy.
- Trial name
- PFROST (NCT03439215)
- Testing
- Lorlatinib
- Where
- 20 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Ricerca Traslazionale
Cancer., Melanoma.
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
This study is a clinical trial phase I/II. Its goal is to determine the safety, tolerability, immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen NY-ESO-1 combined with the adjuvant MPLA from B.
- Conditions
- Cancer., Melanoma., Ovarian Cancer., Lung Cancer.
- Trial name
- NCT01584115
- Testing
- NY-ESO-1 combined with MPLA, NY-ESO-1 combined with MPLA vaccine
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigação em Imunologia
Rectal Cancer, Non-Small Cell Lung Cancer
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients and non-small cell lung cancer…
- Trial name
- NCT06337552
- Testing
- FEED-FF, Standard of Care (SUC)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
This study is a randomized phase III trial that aiming to investigate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) guided hypofractionated radiotherapy (hypo-RT) in patients with locally advanced…
- Trial name
- NCT06545747
- Testing
- DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT, Concurrent chemotherapy
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Sun Yat-sen University
Lung Cancer
Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer
The investigators will evaluate the utility of computer aided image analysis in lung cancer with the aim of predicting treatment response and prognosis.
- Trial name
- NCT03954847
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Non-small Cell Lung Cancer Stage IV
Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)
The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care.
- Trial name
- DigiNet (NCT05818449)
- Testing
- DigiNet intervention
- Where
- 41 sites in Germany
- Volunteers
- 850 people
- Sponsor
- University of Cologne
Lung Neoplasms
Rational Approach to a Unilateral Pleural Effusion2
Recurrent unilateral, non-infectious pleural exudate is suspicious for primary or secondary pleural malignancy. Both conditions are associated with 5-year survival of 10%.
- Trial name
- REPEAT (NCT02834455)
- Testing
- Contrast-enhanced CT, PET-CT
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Simon Reuter
Non-small Cell Lung Cancer, Advanced Solid Malignancies
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
This study is to determine the use of theophylline in patients with NSCLC and advanced solid malignancies and whether treatment with theophylline will help lower or diminish the side effect of diarrhea in patients taking…
- Trial name
- NCT02080078
- Testing
- Theophylline, Erlotinib
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- AHS Cancer Control Alberta
Carcinoma, Small Cell Lung
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
The primary objectives of this study are: 1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive small cell lung cancer (SCLC) as measured by objective response rate 2.
- Trial name
- NCT00435578
- Testing
- Glufosfamide
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Threshold Pharmaceuticals
Stage III NSCLC
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
- Trial name
- SPORADIC (NCT06656598)
- Testing
- Carboplatin, Paclitaxel, Cemiplimab
- Where
- 25 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor…
- Trial name
- NCT02163733
- Testing
- AZD9291 tablets, Pharmacokinetic sampling - AZD9291, Dietary Fasted
- Where
- 13 sites in France, South Korea and 2 more
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer Stage IV
Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
This study is an observational study evaluating the treatment patterns and clinical outcomes after progression on first-line Tislelizumab treatment in advanced NSCLC.
- Trial name
- REALM-Post (NCT06962449)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Mesothelioma, Pleural Mesothelioma
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Despite the best surgical efforts, complete removal of mesothelioma is possible in approximately 30% of the patients. When surgical removal is complete, chemotherapy followed by radiation therapy is recommended as an effort to…
- Trial name
- NCT00895648
- Testing
- Pemetrexed, Cisplatin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Non-Small Cell Lung Cancer
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and…
- Trial name
- NCT00434226
- Testing
- bevacizumab, sunitinib, carboplatin
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
Lung Cancer, Nonsmall Cell
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC).
- Trial name
- FL-ALTER (NCT04028778)
- Testing
- Gefitinib, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Sun Yat-sen University
Locally Advanced or Metastatic NSCLC
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects.
- Trial name
- NCT05631678
- Testing
- Rifampicin; ASK120067, ASK120067;itraconazole
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Lung Cancer
Validation of a Multi-gene Test for Lung Cancer Risk
The purpose of this study is to determine the validity of a multi-gene Lung Cancer Risk Test (LCRT). In the process, the investigators will establish a bank of NBEC samples and corresponding blood samples from individuals…
- Trial name
- NCT01130285
- Testing
- Lung Cancer Risk Test
- Where
- 13 sites in United States
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
Non-Small Cell Lung Cancer
Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the Objective Response Rate of KOS-1584, as a single agent in patients with stage IIIB/IV NSCLC whose disease has progressed following initial chemotherapy.
- Trial name
- NCT00651508
- Testing
- KOS-1584
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb